Simulations Plus, Inc(SLP.US) 2026财年第一季度业绩电话会
文章语言：
简
繁
EN
Share
Minutes
原文
会议摘要
Revenue dipped 3%, yet adjusted EBITDA and EPS met expectations. Positive macro trends and FDA support for in silico methods bolster client spending. Focus on AI-integrated product ecosystem and QSP model advancements. Services segment grows robustly, offsetting software revenue challenges. FY26 guidance unchanged, with revenue projected between $79M and $82M. Investor day set for January 21 to outline strategy.
会议速览
Simulations Plus Announces Q1 FY2026 Financial Results and Q&AThe call opens with a reminder about the financial results conference, emphasizing the update on the quarterly earnings presentation available on the company's website. Forward-looking statements are noted, along with a disclaimer on risks and uncertainties. Non-GAAP measures are mentioned, with reconciliation details provided. The CEO and CFO are set to present, followed by a Q&A session.
First Quarter Financials, Market Trends, and Strategic Advancements in Integrated Product EcosystemThe dialogue outlines a first quarter with revenue down 3%, in line with expectations, highlighting market trends like improved biotech funding and FDA support. It emphasizes strategic priorities for fiscal 2026, focusing on integrating simulation, validated science, cloud, AI, and regulatory modeling to enhance customer pain points and industry alignment. Software and services segments are detailed, noting discovery and development product performance, client renewals, and an 18% increase in services backlog to $20.4 million.
CTI's Q1 Revenue Growth, Strategic Acquisitions, and 2026 GuidanceCTI reported increased Q1 revenue, attributed to strong MedCom business, with development and commercialization services showing growth. The company highlighted a rise in gross margins, particularly in software and services, driven by strategic personnel adjustments and reduced clinic operations revenue. Financially, CTI ended Q1 with $35.7M in cash and no debt, maintaining a strong capital position. Guidance for FY 2026 anticipates revenue between $79M and $82M, with a focus on growth and innovation, supported by strategic acquisitions and investments in science to expand its ecosystem and client support capabilities.
Guidelines for Participating in a Telephone Q&A SessionInstructions are given on how to ask questions and manage one's status in the queue during a telephone Q&A session, including using keypad commands and handling speaker equipment.
Positive Impact of Favorable Tariffs on Budgets and Increased Allocation for Modeling and SimulationThe dialogue discusses how favorable tariffs and most favored nation pricing have stabilized the outlook for clients, leading to a more optimistic spending environment. This has resulted in a robust conversion of proposals into contracts, with some requirements being accelerated. The speaker anticipates an increase in RD budgets for modeling and simulation as a result, indicating a potential opening up of constrained spending environments.
Analysis of QSP Software Licensing Trends and Impact on RevenueDiscussed the variability in QSP software licensing, noting a soft quarter impacted by high sales the previous year. Despite this, QSP remains a rapidly growing sector with high client interest in therapeutic models, though revenue is subject to the lumpy nature of perpetual licenses.
Q&A on Software and Service Revenue Mix and Seasonality in Q2 and Q3The dialogue discusses the expected software and service revenue mix for the remaining quarters, highlighting the seasonal nature of software renewals in Q2 and Q3, and the anticipated acceleration in software licensing due to increased client spending on projects and staffing.
Impact of Industry Consolidation on Software Renewals and Future GuidanceThe dialogue discusses the effects of industry consolidation, particularly large pharma acquiring smaller biotech assets, on software renewal rates. It notes an uptick in consolidation affecting renewals in the latter part of fiscal 2025 but no significant impact in Q1. Guidance for 2026 does not anticipate a major influence from consolidation on renewals.
Radiative Guidance, Backlog Momentum, and Software Revenue TrendsThe dialogue discusses adjustments in radiative guidance, acknowledging improved environments and strong backlog momentum, leading to less back-loaded guidance. It highlights the year-over-year software revenue growth, influenced by past seasonality patterns and proficiency contributions. Medcom's outperformance is noted, suggesting conservative proficiency comp expectations. The conversation underscores the impact of software revenue dynamics and medcom's growth on fiscal year projections.
Services as a Leading Indicator for Software Demand: Historical Trends and Integrated Product VisionHistorical correlation between services and software demand is revisited, with emphasis on its relevance to the current integrated product vision and expanded portfolio, indicating services' predictive value in software market trends.
Impact of Budget Cuts on Service vs. Software Business and Shifts in RD SpendingThe dialogue discusses how budget cuts affected service business more than software sales, highlighting the discretionary nature of service spending. It also covers a strategic reallocation of service resources to product development, increasing RD expenses temporarily, with a focus on upcoming product advancements and investor communications.
Strategies for Enhancing Profitability Through Staff Reorganization and Cost ControlDiscussed reorganization strategies to boost service staff utilization, aiming for 30%-35% services margins. Highlighted maintaining R&D spend at 15%-17% of revenue, sales and marketing at 13%-15%, and reducing Gna expenses as a percentage of revenue, with capitalized software work staying at mid-20%.
Recovery and Growth in Medical Communications Post Proficiency AcquisitionThe dialogue discusses the recovery and growth in medical communications services following the proficiency acquisition, highlighting a positive outlook for fiscal year 26 after a period of budget pressures.
Analysis of Clinical Operations Software Decline and Fee Retention RatesThe dialogue discusses the decline in clinical operations software sales, attributing it to clinical trial startup challenges, and examines fee retention rates, noting a slight drop due to delayed renewals around Thanksgiving.
AI Integration and Future Growth in Pharma PlatformDiscussion on AI enhancements in the platform, favorable customer response, pricing strategy, and future plans for product expansion and revenue generation, with key details to be revealed at an upcoming investor day.
要点回答
Q：What were the financial results for Simulations Plus' first quarter of fiscal year 2026?
A：In the first quarter of fiscal year 2026, Simulations Plus reported revenue that decreased 3% as expected, with adjusted EBITDA at $3.5 million and adjusted EPS at 13 cents, in line with internal expectations.
Q：What are the current trends in the global macro environment that Simulations Plus is dealing with?
A：The positive global macro trends include progress in most favored nation and pricing agreements, reduced tariff threats, and an improving biotech funding environment. At the regulatory level, the FDA has issued guidelines for review and support of in silico methodologies.
Q：What are the priorities of Simulations Plus for fiscal 2026?
A：The priorities for Simulations Plus in fiscal 2026 are to advance towards an integrated product ecosystem combining strengths in validated science, cloud scale performance, AI, and regulatory-grade modeling. The company aims to drive innovation through advanced science, ongoing investment in scientific engines, a connected ecosystem, interoperable products, AI-driven services, intelligent tools, and AI-human collaboration.
Q：How did the revenue from different product categories perform in the first quarter?
A：In the first quarter, software revenue decreased 17% with discovery products contributing 15%, development products 81%, and clinical operations products 4%. Services revenue decreased 3% with development services contributing 71% and commercial services 29%. The company ended the quarter with 302 commercial clients, a 147,000 average revenue per client, an 87% renewal rate, and a 10% trailing 12-month renewal rate.
Q：What was the impact of market conditions and client consolidations on the company's software revenue and renewal rates?
A：Market conditions and client consolidations impacted software revenue and renewal rates, with discovery revenue increasing 3%, development revenue declining 1% for the quarter and growing 1% for the trailing 12 months, and clinical operations revenue declining 82% for the quarter and 28% for the trailing 12 months.
Q：What is the company's guidance for fiscal year 2026?
A：The company's guidance for fiscal year 2026 is as follows: total revenue between $79 to $82 million year over year, revenue growth between 0 to 4%, software mix between 57% to 62%, adjusted EBITDA margin between 26% to 30%, and adjusted diluted earnings per share between $1.3 to $1.10. The second quarter revenue is anticipated to be approximately $21 to $22 million.
Q：What positive commentary regarding most favored nations was mentioned, and how is it expected to impact customer budgets and R&D allocations?
A：Positive commentary included lower tariff risks and the implementation of most favored nation agreements which are stabilizing the outlook for clients. This is expected to have a positive impact on customer budgets and may lead to a greater allocation of R&D budgets towards modeling and simulation.
Q：What effects did the positive economic factors have on the company's service revenue in the November-ending quarter?
A：Positive economic factors such as the implementation of most favored nation agreements and potential tariff reductions led to robust service revenue delivery for the company in the November-ending quarter, despite a constrained spending environment in previous years.
Q：What was the impact of the FDA guidance on QSP software licensing, and how does the company view the current performance of its QSP models?
A：The impact of the FDA guidance on QSP software licensing was not directly addressed in the transcript. However, it is mentioned that the QSP models have experienced a quarter with less activity compared to the year-ago period, but with year-over-year growth expected in therapeutic model licensing. The QSP software revenue is seen as lumpy due to its perpetual license flow, but there is high interest in these models and the QSP space as a whole.
Q：What is the expected mix cadence for software in the remaining three quarters of the fiscal year, and what factors could lead to an improvement in software performance?
A：The expected mix cadence for software in the remaining three quarters of the fiscal year is guided to stay within the range of 57% to 62% for full-year software contribution to revenues. Factors that could lead to an improvement in software performance include accelerated spending by clients, a backlog of projects being initiated, and an increase in staffing within the modeling and simulation departments.
Q：Did the headwind related to the consolidation of large problems worsen in the first quarter, and what is the historical impact of consolidation on software renewal rates?
A：The headwind related to the consolidation of large problems did not worsen in the first quarter. Although there was an uptick in consolidation in the back half of the fiscal year, there were no major contributions from this in the first quarter. Historically, consolidation can be a headwind to software renewals, but it did not significantly impact the company's first quarter results or expectations for the year.
Q：What is the projected impact of proficiency contribution on software revenue growth in the second half of the year?
A：The projected impact of proficiency contribution on software revenue growth in the second half of the year is that the year-over-year increase percentage is expected to step up as the comparison with the back half of the previous year becomes more favorable.
Q：Why was medcom's business performance in the quarter mentioned as exceeding expectations?
A：Medcom's business was mentioned as outperforming beyond expectations in the quarter due to better-than-anticipated results from proficiency software and platform licenses, supported by commercialization and service revenues.
Q：What is the relationship between services and software demand historically?
A：Historically, services have been a leading indicator for software demand as clients tend to constrain spending on services more than software when budgets are cut back. This has a quicker impact on service bookings and, as budgets expand, software upsells occur as clients expand their modeling departments.
Q：What was the rationale behind reallocating services personnel to product development?
A：The rationale behind reallocating services personnel to product development was to rationalize service resources to lower levels of service revenue and improve margins, while retaining valuable assets in research and development (R&D) to accelerate product activity and support the company's product vision.
Q：How did the reallocation affect the profitability side of the business?
A：The reallocation of services personnel to product development resulted in higher R&D expenses due to additional personnel in accelerating product activity. However, this is expected to be averaged out over the course of the year as revenue increases in the latter part of the year due to seasonal patterns.
Q：What was the impact of the reorganization on the company's financials?
A：The reorganization led to a reduction in services staff to increase utilization targets, reevaluation of work in product development, and a focus on growing software revenue. Expenses have continued to be invested in the area, with the goal of keeping operating expenses around 50% of revenue for the year. Software capitalization and capitalized software expenses are running about the same, with a mid-20% allocation of work into capitalized software.
Q：What does the company's investment in capitalized software signify?
A：The company's investment in capitalized software signifies a focus on product development and an expectation that future software revenue growth will result from the increased investment in research and development and the subsequent development of new products.
Q：What are the two revenue streams generated by the proficiency acquisition?
A：The two revenue streams generated by the proficiency acquisition were the proficiency software platform, the training platform, and clinical operations, and medical communications.
Q：What has been the impact of the proficiency acquisition on medical communication service revenues?
A：The medical communication service revenues were under pressure in the back half of the fiscal year due to budget pullbacks. However, in the first quarter, the revenue was a bit above expectations and indicative of more active spend by clients. The outlook for fiscal year 26 is positive.
Q：Why did clinical operations software experience a year-over-year decline in revenue?
A：Clinical operations software experienced a year-over-year decline in revenue due to clinical trial startup challenges in the back half of fiscal year 25, despite a strong initial second quarter contribution upon acquisition.
Q：Is the 88% fee retention rate in line with expectations?
A：Yes, the 88% fee retention rate is in line with expectations, historically the rate has been 90% plus, and despite a couple of renewals not being signed over Thanksgiving weekend, the renewal rate was considered relatively good.
Q：How is the ongoing AI integration with the core platform and the initial rollout going?
A：The initial release of new AI features has received a very favorable response. There has been aggressive pricing with AI technology embedded in the base model, and there are opportunities to monetize it further through modules and new products.
Q：Are there plans to launch any new verticals or products within the existing platform over the next 12 to 18 months?
A：The company primarily focuses on drug development, discovery, and clinical development, commercialization, clinical ops, and QP capabilities within the chemical space, agribusiness, cosmetics, and a few other areas. They plan to discuss their strategy for creating new revenue streams at the investor day but do not anticipate it to be significantly impactful to the 2026 revenue.
Simulations Plus, Inc.
Follow
